Case Report Necrotizing fasciitis of the perineum (Fournier’s gangrene) with Diabetes Mellitus on Empagliflozin (Jardiance) : Fournier’s Gangrene with Diabetes on Empagliflozin: Clinical Perspectives Bombay

MANMOHAN KAMAT; VISHAL RATHOD; AMISHI RATHOD; Sanket Desai

doi:10.15713/ins.bhj.158

Authors

DR. MANMOHAN KAMAT
DR. VISHAL RATHOD
DR. AMISHI RATHOD
DR. SANKET DESAI a:1:{s:5:"en_US";s:17:"Nanavati Hospital";}

DOI:

https://doi.org/10.15713/ins.bhj.158

Abstract

Empagliflozin (Jardiance) is in a class of newer drugs used to treat type 2 diabetes associated with a rare, life-threatening genital area infection called necrotizing fasciitis of the perineum (Fournier’s gangrene). We report a case with an old man who presented with necrotizing fasciitis of the perineum (Fournier’s gangrene) with Diabetes of 4 years duration, on Empagliflozin (Jardiance). This patient developed Pseudomonas infection. Carbapenem-resistant Enterococci of the perineum, and required extensive debridement with diversion colostomy and reconstruction of the sphincter.

Empagliflozin is a class of newer drugs used to treat type 2 diabetes. It is associated with a rare, life-threatening genital area infection called necrotizing fasciitis of the perineum (Fournier’s gangrene). Fournier’s gangrene is rare necrotizing fasciitis of the perineum and genitals caused by a mixture of aerobic and anaerobic microorganisms entering the layer of tissue just under the skin in the perineum, the space between the anus and scrotum in men, and the anus and vulva in women. Infection most commonly arises from the skin, urethra, or rectal regions. We report a case of Fournier's Gangrene in a patient during a period of management with empagliflozin

References

R. Vick and C. C. Carson III, “Fournier's disease,” Urologic Clinics of North America, vol. 26, no. 4, pp. 841–849, 1999.View at: Publisher Site | Google Scholar

Sorensen MD, Krieger JN. Fournier’s gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97:249–59.

N. Eke, “Fournier's gangrene: a review of 1726 cases,” British Journal of Surgery, vol. 87, no. 6, pp. 718–728, 2000.View at: Publisher Site | Google Scholar

J. Torremadé Barreda, M. Millán Scheiding, C. Suárez Fernández, J.M. Cuadrado Campaña, J. Rodríguez Aguilera, E. Franco Miranda, et al.

Fournier gangrene. A retrospective study of 41 cases.

Cir Esp, 87 (2010), pp. 218-223

R. Vick and C. C. Carson III, “Fournier's disease,” Urologic Clinics of North America, vol. 26, no. 4, pp. 841–849, 1999.View at: Publisher Site | Google Scholar

Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med. 2019;170:764–69. [PubMed] [Google Scholar]

C.V. Dave, S. Schneeweiss, E. Patorno.

Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier gangrene among men.JAMA Intern Med, (2019),